The Charter of the French Language and its regulations govern the consultation of English-language content.


2301 Avenue d’Estimauville Québec (Québec) G1E 0N5 Canada
Chargé d’enseignement clinique, Faculté de médecine, Médecine-Département de psychiatrie et de neurosciences, Université Laval
Chercheur, CERVO
Axe de recherche:
Neurosciences cliniques et cognitives
Laurent Béchard; Elizabeth Anderson; Olivier Corbeil; Maxime Huot-Lavoie; Sébastien Brodeur; Amal Abdel-Baki; Charles Massé; Mina Gabriel-Courval; Marie-Ève Coté; Annie LeBlanc; Marc-André Roy; Marie-France Demers; Sophie Lauzier
Dans: BJPsych Open, vol. 11, no 5, p. e193, 2025, ISSN: 2056-4724.
@article{pmid40904211,
title = {Factors shaping the decision-making process to continue or discontinue antipsychotics: exploratory qualitative study of 12 individuals in remission from first-episode psychosis},
author = {Laurent Béchard and Elizabeth Anderson and Olivier Corbeil and Maxime Huot-Lavoie and Sébastien Brodeur and Amal Abdel-Baki and Charles Massé and Mina Gabriel-Courval and Marie-Ève Coté and Annie LeBlanc and Marc-André Roy and Marie-France Demers and Sophie Lauzier},
doi = {10.1192/bjo.2025.10817},
issn = {2056-4724},
year = {2025},
date = {2025-09-01},
journal = {BJPsych Open},
volume = {11},
number = {5},
pages = {e193},
abstract = {BACKGROUND: The decision-making process regarding antipsychotic continuation or discontinuation following remission from first-episode psychosis (FEP) remains complex and underresearched. While discontinuation increases the risk of relapse, concerns over long-term side-effects such as metabolic disturbances and extrapyramidal symptoms also exist. Current guidelines recommend maintaining antipsychotics for 1-5 years, emphasising shared decision-making (SDM) between clinicians and patients.nnAIMS: This study aimed to explore the decision-making process and describe the factors influencing the decision to discontinue or continue antipsychotic treatment following remission from FEP, from the patients' perspective.nnMETHOD: A descriptive qualitative study was conducted with 12 individuals in remission from FEP who received care at early intervention services in Quebec, Canada. Data were collected through online semi-structured interviews and analysed thematically to identify key factors influencing treatment decisions.nnRESULTS: The decision-making process was activated by treatment reflection triggers and shaped by various perceptions (of illness, treatment and stigma) and relationships (with friends, family and the clinical team), ultimately leading to decisions to either discontinue, continue (at standard or reduced dose) or remain ambivalent. This dynamic process was guided by participants' motivators, such as well-being and societal contribution. Most participants felt that discontinuation discussions were not initiated by the clinical team.nnCONCLUSIONS: The decision-making process is driven by motivators that were found to be linked to the concept of personal recovery. This study highlights the need for proactive, personalised discussions between clinicians and patients. Future research should focus on decision aids tailored to the FEP population to support SDM and improve treatment outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Mélanie Couture; Josiane Courteau; Sébastien Brodeur; Yohann M Chiu; Mireille Courteau; Émilie Dubé; Nina Thomas; Alain Lesage; Éric Fombonne; Isabelle Dufour
Male and Female Healthcare Trajectories in Autism: Are There Any Differences Considering Age at Diagnosis and Intellectual or Developmental Disabilities Status? Article de journal
Dans: Autism Res, vol. 18, no 8, p. 1674–1692, 2025, ISSN: 1939-3806.
@article{pmid40568737,
title = {Male and Female Healthcare Trajectories in Autism: Are There Any Differences Considering Age at Diagnosis and Intellectual or Developmental Disabilities Status?},
author = {Mélanie Couture and Josiane Courteau and Sébastien Brodeur and Yohann M Chiu and Mireille Courteau and Émilie Dubé and Nina Thomas and Alain Lesage and Éric Fombonne and Isabelle Dufour},
doi = {10.1002/aur.70072},
issn = {1939-3806},
year = {2025},
date = {2025-08-01},
journal = {Autism Res},
volume = {18},
number = {8},
pages = {1674--1692},
abstract = {The aim of this study was to compare the healthcare trajectories (HCTs) 2 years after a first diagnosis of autism according to sex, age at diagnosis, and intellectual or developmental disabilities (IDD) status. This is a retrospective cohort study using health administrative data from Québec, Canada. The cohort included all individuals with a first diagnosis of autism registered by a physician between April 2012 and March 2015. HCTs were stratified by sex, presence of IDD, and age at diagnosis (youth, adult), and analyzed using state sequence analysis across healthcare settings, providers, and reasons for use. Our cohort included 5289 individuals, 76.6% were male, and 26.3% were adults at the time of diagnosis. The healthcare use decreased slightly over time, though intensity was higher in females. Sex differences in HCTs were strongly influenced by IDD status and age at diagnosis. While no significant sex differences were observed in HCTs for individuals with IDD diagnosed with autism in adulthood, the psychiatric condition profiles showed notable differences between males and females. Hospital days nearly doubled for females diagnosed in childhood compared to males, while males with IDD diagnosed with autism in childhood and males without IDD diagnosed in adulthood had fewer physical illness visits. Although physical and mental health challenges appear largely managed in ambulatory care during youth, high hospitalization rates in those diagnosed in adulthood, particularly females and those with IDD, highlight concerns about continuity of care and avoidable hospitalizations for these subgroups of patients.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Maxime Huot-Lavoie; Laurent Béchard; Olivier Corbeil; Olivier Roy; Sophie L’Heureux; Ingrid Salvini; Catherine Lehoux; Anne-Marie Essiambre; Chantale Thériault; Sébastien Brodeur; Marie-France Demers; Yasser Khazaal; Marc-André Roy
Lived experience of gaming disorder among people with psychotic disorders: implications for tailored interventions and clinical management Article de journal
Dans: Curr Opin Psychiatry, vol. 38, no 4, p. 295–301, 2025, ISSN: 1473-6578.
@article{pmid40403141,
title = {Lived experience of gaming disorder among people with psychotic disorders: implications for tailored interventions and clinical management},
author = {Maxime Huot-Lavoie and Laurent Béchard and Olivier Corbeil and Olivier Roy and Sophie L'Heureux and Ingrid Salvini and Catherine Lehoux and Anne-Marie Essiambre and Chantale Thériault and Sébastien Brodeur and Marie-France Demers and Yasser Khazaal and Marc-André Roy},
doi = {10.1097/YCO.0000000000001013},
issn = {1473-6578},
year = {2025},
date = {2025-07-01},
journal = {Curr Opin Psychiatry},
volume = {38},
number = {4},
pages = {295--301},
abstract = {PURPOSE OF REVIEW: Despite growing recognition of the impact of Gaming Disorder in individuals with psychotic disorders, little is known about the clinical and personal implications of this dual diagnosis. Preliminary data suggest that Gaming Disorder may be associated with increased psychotic symptoms and reduced occupational and social functioning. However, insight from lived experience remain largely absent, despite their importance.nnRECENT FINDINGS: This review synthesizes recent literature on the comorbidity between Gaming Disorder and psychotic disorders, highlighting the scarcity of research in this emerging field. It also presents preliminary findings from an ongoing qualitative study focussing on the lived experiences of individuals receiving early psychosis intervention. These data focus on participants' motivations for gaming and their perceptions of both positive and negative effects gaming has on their life.nnSUMMARY: This review underscores the significant lack of data on the dual diagnosis of Gaming Disorder and psychosis. Early qualitative insights reveal diverse gaming motivations, including symptom regulation, anxiety management, cognitive stimulation, and social connection. These first-person accounts emphasize the functional role of gaming and the need for recovery-oriented care. Integrating lived experience into research and clinical practice can improve relevance, support nuanced interventions, and advance our understanding of behavioral addictions in early psychosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Isabelle Dufour; Yohann Chiu; Sébastien Brodeur; Mireille Courteau; Josiane Courteau; Émilie Dubé; Alain Lesage; Éric Fombonne; Mélanie Couture
Pathways to autism diagnosis in adulthood Article de journal
Dans: J Neurodev Disord, vol. 17, no 1, p. 35, 2025, ISSN: 1866-1955.
@article{pmid40596839,
title = {Pathways to autism diagnosis in adulthood},
author = {Isabelle Dufour and Yohann Chiu and Sébastien Brodeur and Mireille Courteau and Josiane Courteau and Émilie Dubé and Alain Lesage and Éric Fombonne and Mélanie Couture},
doi = {10.1186/s11689-025-09627-3},
issn = {1866-1955},
year = {2025},
date = {2025-07-01},
journal = {J Neurodev Disord},
volume = {17},
number = {1},
pages = {35},
abstract = {BACKGROUND: This study explored Trajectories of Diagnoses (TDs) preceding a first diagnosis of autism in adulthood.nnMETHODS: This retrospective cohort study used health administrative data from Quebec, Canada, and included all adults with a first recorded diagnosis of autism between 2012 and 2017. A TDs was defined as a succession of medical records of psychiatric and/or neurodevelopmental conditions over time. These TDs were retrospectively analyzed from 2002 to 2017, using a state sequence analysis of diagnoses, in order: Autism, Intellectual or developmental disabilities (IDDs), Schizophrenia spectrum disorder (SSD), Bipolar Disorder (BD), Depressive Disorder (DD), Anxiety Disorder (AD), Attention-deficit/hyperactivity disorder (ADHD), and Other psychiatric and/or neurodevelopmental conditions.nnRESULTS: The cohort included 2799 adults with a first recorded diagnosis of autism between 2012 and 2017. Several psychiatric and/or neurodevelopmental conditions were recorded since 2002, including AD (77.5%), DD (58.0%), SSD (49.4%), BD (48.3%), and IDDs (33.2%). Results revealed 5 distinct types of TDs. Types 1 (63.8%), 2 (17.6%) and 3 (6%) represented individuals in younger age groups with similar characteristics but with very different sequences of diagnoses, characterized by mixed diagnoses in type 1, SSD and AD in Type 2, and IDDs, DD, AD, and ADHD in type 3. Types 4 and 5 (9.0% and 3.6%), representing middle-aged/older groups, displayed distinctive TDs associated with high healthcare use, almost entirely associated with SSD (Type 4) and BD (Type 5).nnCONCLUSION: This study proposes a complementary examination of the multiple pathways to diagnosis experienced by adults, highlighting the need to address differential diagnosis and co-occurring psychiatric and neurodevelopmental conditions.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Olivier Corbeil; Élizabeth Anderson; Laurent Béchard; Charles Desmeules; Maxime Huot-Lavoie; Lauryann Bachand; Sébastien Brodeur; Pierre-Hugues Carmichael; Christian Jacques; Marco Solmi; Isabelle Giroux; Michel Dorval; Marie-France Demers; Marc-André Roy
Reply to: Why does problem gambling in psychotic disorders pose such a challenge for comprehension? Divers
2025, ISSN: 1600-0447.
@misc{pmid38970223,
title = {Reply to: Why does problem gambling in psychotic disorders pose such a challenge for comprehension?},
author = {Olivier Corbeil and Élizabeth Anderson and Laurent Béchard and Charles Desmeules and Maxime Huot-Lavoie and Lauryann Bachand and Sébastien Brodeur and Pierre-Hugues Carmichael and Christian Jacques and Marco Solmi and Isabelle Giroux and Michel Dorval and Marie-France Demers and Marc-André Roy},
doi = {10.1111/acps.13730},
issn = {1600-0447},
year = {2025},
date = {2025-01-01},
urldate = {2024-07-01},
journal = {Acta Psychiatr Scand},
volume = {151},
number = {1},
pages = {102--104},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}
Sébastien Brodeur; Yohann M Chiu; Josiane Courteau; Marc Dorais; Dominic Oliver; Emmanuel Stip; Marie-Josée Fleury; Marc-André Roy; Alain Vanasse; Alain Lesage; Jacinthe Leclerc
Medication Exposure and Mortality in Patients With Schizophrenia Article de journal
Dans: JAMA Netw Open, vol. 7, no 11, p. e2447137, 2024, ISSN: 2574-3805.
@article{pmid39576638,
title = {Medication Exposure and Mortality in Patients With Schizophrenia},
author = {Sébastien Brodeur and Yohann M Chiu and Josiane Courteau and Marc Dorais and Dominic Oliver and Emmanuel Stip and Marie-Josée Fleury and Marc-André Roy and Alain Vanasse and Alain Lesage and Jacinthe Leclerc},
doi = {10.1001/jamanetworkopen.2024.47137},
issn = {2574-3805},
year = {2024},
date = {2024-11-01},
journal = {JAMA Netw Open},
volume = {7},
number = {11},
pages = {e2447137},
abstract = {IMPORTANCE: The use of antipsychotics, antidepressants, and benzodiazepines may influence the risk of mortality in people with schizophrenia. However, many observational studies have not accounted for immortal time bias (ITB), which occurs when there is a period during which patients in the exposed group are necessarily alive and misclassified as exposed (the period between start of follow-up and initiation of drug). Ignoring ITB may lead to misinterpretation of the association between these drugs and mortality.nnOBJECTIVES: To examine whether the cumulative dose of antipsychotics, antidepressants, and benzodiazepines is associated with mortality risk in patients with schizophrenia and discuss the potential impacts of ignoring ITB.nnDESIGN, SETTING, AND PARTICIPANTS: This cohort study used administrative data from Québec, Canada, including patients aged 17 to 64 years diagnosed with schizophrenia between January 1, 2002, and December 31, 2012. Data analysis was performed from June 22, 2022, to September 30, 2024.nnMAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, with follow-up from January 1, 2013, to December 31, 2017, or until death. Mortality risk was assessed for low, moderate, and high exposure to antipsychotics, antidepressants, and benzodiazepines. Cox proportional hazards regression models with time-fixed exposure (not controlling for ITB) and time-dependent exposure (controlling for ITB) were performed.nnRESULTS: The cohort included 32 240 patients (mean [SD] age, 46.1 [11.6] years; 19 776 [61.3%] men), of whom 1941 (6.0%) died during follow-up. No dose-response association was found for antipsychotics with mortality using the time-fixed method. However, high-dose antipsychotic use was associated with increased mortality after correcting for ITB (adjusted hazard ratio [AHR], 1.28; 95% CI, 1.07-1.55; P = .008). Antidepressants showed a reduced mortality risk using the time-fixed method, but only at high doses when correcting for ITB (AHR, 0.86; 95% CI, 0.74-1.00; P = .047). Benzodiazepines were associated with increased mortality risk regardless of the method.nnCONCLUSIONS AND RELEVANCE: The findings of this study do not dispute the known efficacy of antipsychotics in schizophrenia, but they call into question the magnitude of long-term mortality benefits.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Charles Desmeules; Olivier Corbeil; Maxime Huot-Lavoie; Laurent Béchard; Sébastien Brodeur; Marie-France Demers; Marc-André Roy; Jessica Deslauriers
Psychotic Disorders and exosomes: An overview of current evidence and future directions Article de journal
Dans: Psychiatry Res, vol. 339, p. 116066, 2024, ISSN: 1872-7123.
@article{pmid38996632,
title = {Psychotic Disorders and exosomes: An overview of current evidence and future directions},
author = {Charles Desmeules and Olivier Corbeil and Maxime Huot-Lavoie and Laurent Béchard and Sébastien Brodeur and Marie-France Demers and Marc-André Roy and Jessica Deslauriers},
doi = {10.1016/j.psychres.2024.116066},
issn = {1872-7123},
year = {2024},
date = {2024-09-01},
journal = {Psychiatry Res},
volume = {339},
pages = {116066},
abstract = {Due to its reliance on heterogeneous symptomatology, the accurate diagnosis of psychotic disorders remains a challenging task in clinical practice. Precise and early diagnosis of psychotic disorders facilitates early intervention, which has been shown to have substantial benefits for long-term outcomes. Still, the lack of specific biomarkers is an important limitation in early diagnosis and intervention. Exosomes, which act as messengers between cells, including brain cells, contain a vast array of molecules that hold promise for unveiling disorder-specific abnormalities. In this review, we discuss recent evidence highlighting the potential of circulating exosomes and brain-derived exosomes as valuable tools for the identification of accessible, non-invasive, and blood-based biomarkers of psychotic symptomatology and risk. We discuss current limitations in biomarker discovery studies focusing on exosomes. To enhance diagnosis specificity and treatment response, we also provide guidance for future investigations that need to target biomarkers of risk and relapse, as well as consider duration of untreated psychosis, biological sex, and other factors in the multifactorial biosignature of psychosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Olivier Corbeil; Laurent Béchard; Élizabeth Anderson; Maxime Huot-Lavoie; Charles Desmeules; Lauryann Bachand; Sébastien Brodeur; Pierre-Hugues Carmichael; Christian Jacques; Marco Solmi; Michel Dorval; Isabelle Giroux; Marc-André Roy; Marie-France Demers
Prevalence of schizophrenia spectrum and other psychotic disorders in problem gambling: A systematic review and meta-analysis Article de journal
Dans: Eur Psychiatry, vol. 67, no 1, p. e56, 2024, ISSN: 1778-3585.
@article{pmid39320504,
title = {Prevalence of schizophrenia spectrum and other psychotic disorders in problem gambling: A systematic review and meta-analysis},
author = {Olivier Corbeil and Laurent Béchard and Élizabeth Anderson and Maxime Huot-Lavoie and Charles Desmeules and Lauryann Bachand and Sébastien Brodeur and Pierre-Hugues Carmichael and Christian Jacques and Marco Solmi and Michel Dorval and Isabelle Giroux and Marc-André Roy and Marie-France Demers},
doi = {10.1192/j.eurpsy.2024.1777},
issn = {1778-3585},
year = {2024},
date = {2024-09-01},
journal = {Eur Psychiatry},
volume = {67},
number = {1},
pages = {e56},
abstract = {BACKGROUND: High rates of psychiatric comorbidities have been found in people with problem gambling (PBG), including substance use, anxiety, and mood disorders. Psychotic disorders have received less attention, although this comorbidity is expected to have a significant impact on the course, consequences, and treatment of PBG. This review aimed to estimate the prevalence of psychotic disorders in PBG.nnMETHODS: Medline (Ovid), EMBASE, PsycINFO (Ovid), CINAHL, CENTRAL, Web of Science, and ProQuest were searched on November 1, 2023, without language restrictions. Studies involving people with PBG and reporting the prevalence of schizophrenia spectrum and other psychotic disorders were included. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal checklist for systematic reviews of prevalence data. The pooled prevalence of psychotic disorders was calculated using a random effects generalized linear mixed model and presented with forest plots.nnRESULTS: Of 1,271 records screened, 22 studies ( = 19,131) were included. The overall prevalence of psychotic disorders was 4.9% (95% CI, 3.6-6.5%, = 88%). A lower prevalence was found in surveyed/recruited populations, compared with treatment-seeking individuals and register-based studies. No differences were found for factors such as treatment setting (inpatient/outpatient), diagnoses of psychotic disorders (schizophrenia only/other psychotic disorders), and assessment time frame (current/lifetime). The majority of included studies had a moderate risk of bias.nnCONCLUSIONS: These findings highlight the relevance of screening problem gamblers for schizophrenia spectrum and other psychotic disorders, as well as any other comorbid mental health conditions, given the significant impact such comorbidities can have on the recovery process.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Maxime Huot-Lavoie; Charles Desmeules; Olivier Corbeil; Laurent Béchard; Sébastien Brodeur; Anne-Marie Essiambre; Chantale Thériault; Elizabeth Anderson; Lauryann Bachand; Zain Al-Aabideen Haider; Amal Abdel-Baki; Yasser Khazaal; Isabelle Giroux; Marie-France Demers; Marc-André Roy
Impact of gaming disorder on first episode psychosis patients’ evolution: Protocol for a multicentered prospective study Article de journal
Dans: Early Interv Psychiatry, vol. 18, no 6, p. 439–445, 2024, ISSN: 1751-7893.
@article{pmid38059702,
title = {Impact of gaming disorder on first episode psychosis patients' evolution: Protocol for a multicentered prospective study},
author = {Maxime Huot-Lavoie and Charles Desmeules and Olivier Corbeil and Laurent Béchard and Sébastien Brodeur and Anne-Marie Essiambre and Chantale Thériault and Elizabeth Anderson and Lauryann Bachand and Zain Al-Aabideen Haider and Amal Abdel-Baki and Yasser Khazaal and Isabelle Giroux and Marie-France Demers and Marc-André Roy},
doi = {10.1111/eip.13482},
issn = {1751-7893},
year = {2024},
date = {2024-06-01},
journal = {Early Interv Psychiatry},
volume = {18},
number = {6},
pages = {439--445},
abstract = {AIMS: The objective of this study is to underline the impact of Gaming Disorder on the clinical evolution of patients with First Episode Psychosis. The specific aims of the study are to determine the prevalence of gaming disorder among those patients and assess the consequences of gaming on their clinical trajectory.nnMETHODS: This is a prospective multicenter cohort study that will enrol 800 patients diagnosed with a first episode psychosis, with a follow-up period of up to 3 years. Using a systematic screening procedure for gaming disorder, the clinical staff will assess patients gaming habits at admission and every 6 months thereafter. Information from patients' medical records will also be extracted using the same timeframe.nnRESULTS: The patients' characteristics at admission and during follow-up will be presented in the form of descriptive statistics and compared between different subgroups of patients using uni- and multivariate logistic regression models. Repeated measures ANCOVA will also be performed to analyse the impact of gaming disorders on patients' clinical path as assessed by the Positive and Negative Syndrome Scale and the Clinical Global Impression scale, considering covariates such as psychiatric diagnosis, pharmacological treatment, age, sex/gender, and duration of untreated psychosis.nnCONCLUSION: These findings will guide the development of prevention, detection, and treatment strategies for the comorbidity between gaming disorder and first episode psychosis, ultimately improving the patients' recovery.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Isabelle Dufour; Sébastien Brodeur; Josiane Courteau; Marc-André Roy; Alain Vanasse; Amélie Quesnel-Vallee; Isabelle Vedel
Care trajectories around a first dementia diagnosis in patients with serious mental illness Article de journal
Dans: Geriatr Gerontol Int, vol. 24, no 6, p. 577–586, 2024, ISSN: 1447-0594.
@article{pmid38710639,
title = {Care trajectories around a first dementia diagnosis in patients with serious mental illness},
author = {Isabelle Dufour and Sébastien Brodeur and Josiane Courteau and Marc-André Roy and Alain Vanasse and Amélie Quesnel-Vallee and Isabelle Vedel},
doi = {10.1111/ggi.14889},
issn = {1447-0594},
year = {2024},
date = {2024-06-01},
journal = {Geriatr Gerontol Int},
volume = {24},
number = {6},
pages = {577--586},
abstract = {AIM: To develop a typology of care trajectories (CTs) 1 year before and after a first dementia diagnosis in individuals aged ≥65 years, with prevalent schizophrenia or bipolar disorder.nnMETHODS: This was a longitudinal, retrospective cohort study using health administrative data (1996-2016) from Quebec (Canada). We selected patients aged ≥65 years with an incident diagnosis of dementia between 1 January 2014 and 31 December 2016, and a diagnosis of schizophrenia and/or or bipolar disorder. A CT typology was generated by a multidimensional state sequence analysis based on the "6 W" model of CTs. Three dimensions were considered: the care setting ("where"), the reason for consultation ("why") and the specialty of care providers ("which").nnRESULTS: In total, 3868 patients were categorized into seven distinct types of CTs, with varying patterns of healthcare use and comorbidities. Healthcare use differed in terms of intensity, but also in its distribution around the diagnosis. For instance, whereas one group showed low healthcare use, healthcare use abruptly increased or decreased after the diagnosis in other groups, or was equally distributed. Other significant differences between CTs included mortality rates and use of long-term care after the diagnosis. Most patients (67%) received their first dementia diagnosis during hospitalization.nnCONCLUSIONS: Our innovative approach provides a unique insight into the complex healthcare patterns of people living with serious mental illness and dementia, and provides an avenue to support data-driven decision-making by highlighting fragility areas in allocating care resources. Geriatr Gerontol Int 2024; 24: 577-586.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}